… the DAPA-HF trial, the SGLT2 inhibitor dapagliflozin reduced the risk of worsening heart
failure (HF) and death in patients with HF … was consistent in relation to background HF therapy. …

… Association functional class ≥ II, a left ventricular ejection fraction ≤ 40%, an elevated N-…
DAPA-HF, which is comparing dapagliflozin 10 mg once daily to matching placebo. In patients …

… We have reported that the benefits of dapagliflozin on cardiovascular outcomes were
consistent in patients with and without type 2 diabetes in DAPA-HF. The current data extend these …

… There was a significant benefit of dapagliflozin on death from CV causes in DAPA-HF (HR …
Using the pooled analysis of DAPA-HF and DELIVER, the number of patients with HF who …

… in patients with heart failure and … of dapagliflozin, which lowers systolic blood pressure
(SBP),according to baseline SBP in Dapagliflozin and Prevention of Adverse Outcomes in Heart …

… of mortality and heart failure hospitalization and improved symptoms in patients with heart
failure and reduced ejection fraction. We examined the effects of dapagliflozin according to …

… The beneficial effects of dapagliflozin on heart failure … indicate that dapagliflozin significantly
improves heart failure–… by the Kansas City Cardiomyopathy Questionnaire, with the benefits …

… The key finding of the present analyses is that the benefits of dapagliflozin in DAPA-HF
were obtained regardless of the use of background diuretic therapy or dose of diuretic therapy. …

… In conclusion, in patients with HFrEF in DAPA-HF, those with anaemia had worse
outcomes. Dapagliflozin corrected anaemia more often than placebo and improved outcomes, …

… This study assessed the efficacy and safety of dapagliflozin in patients who … in DAPA-HF,
we could not directly assess the potential incremental value of treatment with both dapagliflozin …